Soligenix Appoints Former White House Economic Advisor Tomas J. Philipson to Strategic Role

Soligenix Inc. has announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor to the late-stage biopharmaceutical company. Dr. Philipson brings extensive expertise in U.S. economic and healthcare policy, having previously served as acting chairman of the White House Council of Economic Advisers and advised major healthcare organizations including the FDA and CMS. His background includes significant academic, business, and government experience that positions him uniquely to support Soligenix's mission.

The appointment comes at a critical juncture for Soligenix as the company advances its lead product candidate HyBryte™ through confirmatory Phase 3 trials. Christopher J. Schaber, PhD, CEO of Soligenix, emphasized that Philipson's expertise and relationships will be instrumental in navigating the complex regulatory landscape and advancing toward commercialization. HyBryte™ represents a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, addressing a significant unmet medical need in rare diseases.

Dr. Philipson currently serves as Managing Partner of MEDA Ventures and holds positions on several corporate boards, bringing additional business acumen to Soligenix's strategic planning. His appointment signals the company's commitment to strengthening its leadership as it moves closer to potential regulatory approvals and worldwide commercialization. The full details of the appointment are available in the official announcement at https://ibn.fm/M7YEd.

The implications of this strategic hire extend beyond Soligenix's immediate development pipeline. For investors and the broader biopharmaceutical industry, the addition of a former White House economic advisor demonstrates Soligenix's serious commitment to navigating the complex intersection of healthcare policy, regulatory requirements, and market access. Philipson's background in economic policy could prove particularly valuable as the company prepares for pricing, reimbursement, and market adoption strategies for HyBryte™ and other pipeline candidates.

Soligenix's development pipeline includes multiple programs across its Specialized BioTherapeutics and Public Health Solutions business segments. The company's work extends beyond CTCL treatment to include potential therapies for psoriasis, inflammatory diseases, and vaccine candidates for threats including ricin toxin, filoviruses, and COVID-19. Many of these programs have received government support from agencies including NIAID, DTRA, and BARDA, highlighting the strategic importance of Philipson's government experience and relationships.

For patients suffering from rare diseases with limited treatment options, this appointment represents another step toward potentially bringing new therapies to market. The company's focus on rare diseases with unmet medical needs aligns with Philipson's stated commitment to supporting Soligenix's mission. As the biopharmaceutical company continues to advance its clinical programs, the strategic guidance from experienced advisors like Philipson could accelerate the delivery of innovative treatments to patients who need them most.